Peter A. Noseworthy, M.D.

1. Obtain AliveCor ECG Recordings from subjects at the time of clinically indicated ECGs over the course their anti-arrhythmic drug loading hospital admission. 
2. Create and refine an AliveCor algorithm to accurately measure a patient’s QT interval and heart rate corrected QTc value and validate/compare the results against the 12- lead ECGs on record.
3. Obtain AliveCor ECG recordings at the time of daily clinically indicated electrolyte panels to further develop and refine a Potassium screening algorithm.

The purpose of this study is to describe and assess the performance of a surface ECG AI algorithm to detect patients with asymptomatic left ventricular dysfunction.

The purpose of this study is to assess the ability of common genetic variants in aggregate to predict drug-induced QT prolongation in patients being started on dofetilide. We will examine the predictiveness of a QT genotype score on QT prolongation in patients admitted for dofetilide initiation.
 

The primary objective of this study is to determine whether etripamil nasal spray (NS) 70 mg is superior to placebo at terminating episodes of Paroxysmal Supraventricular Tachycardia (PSVT) in an outpatient setting.

The purpose of this study is to help researchers better understand the impact of wearable devices on patient experience and clinical trends following a cardioversion.

The primary objective of this study is to determine whether etripamil nasal spray (NS) 70 mg is superior to placebo at terminating episodes of PSVT in an outpatient setting.

The objective of this project is to evaluate a treatment decision aid for patients with atrial fibrillation.

The purpose of this study is to determine if common genetic variants that underlie the QT interval are also associated with medication-induced torsade de pointes (TdP).